

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Deshpande et al.

Serial No.: 09/791,153

Group Art Unit No.: 1644

Filed: February 22, 2001

Examiner: Schwadron, Ronald B.

For: Selective Binding Agents of
Osteoprotegerin Binding Protein

Confirmation No.: 7448

Docket No.: A-633A

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT
AND PRELIMINARY AMENDMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A response to the Notice of Non-Compliant Amendment dated July 22, 2009 and a Preliminary Amendment are filed herewith.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

Date: _____ August 21, 2009

/Nola J. Diamond/

Nola J. Diamond

AMENDMENT

Please amend the claims as follows.

Listing of Claims

1-39. **(cancelled)**

40. **(currently amended)** An antibody or antigen binding domain which recognizes a DE epitope on human osteoprotegerin binding protein (OPGbp) wherein the DE epitope comprises the amino acid sequence from residues 212 to 250 of human OPGbp as shown in Figure 29 (SEQ ID NO: 158).

41. **(currently amended)** An The antibody or antigen binding domain of Claim 40 which recognizes a wherein the DE epitope comprises residues 230 to 234 of or human OPGbp as shown in Figure 29 (SEQ ID NO: 158).

42. **(currently amended)** The antibody or antigen binding domain of Claim 40 or 41 wherein the DE epitope comprises which recognizes the sequence Asp-Leu-Ala-Thr-Glu of human OPGbp.

43. **(original)** An antibody or antigen binding domain which binds to murine OPGbp comprising the amino acid substitutions S229D, V230L, P231A, and D233E, but does not bind to murine OPGbp lacking said substitutions.

44. **(currently amended)** The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which inhibits the formation of or activation of osteoclasts.

45. **(original)** The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which inhibits bone resorption.

46-51. (cancelled)

52. (currently amended) An The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which binds selectively to human OPGbp with a dissociation constant (KD) of about 1nM or less.

53. (currently amended) An The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which binds selectively to human OPGbp with a dissociation rate constant (kd) of about 3 x 10-3 or less.

54. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antibody is a monoclonal antibody.

55. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antibody is a chimeric, humanized, human, single chain or bispecific antibody.

56. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antigen binding domain is a Fab, F(ab'), F(ab)¹, Fv or sFv fragment.

57. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which comprises an IgG isotype.

58. (new) A composition comprising the antibody or antigen binding domain of Claims 40, 41, 42 or 43 and a pharmaceutically acceptable agent.

Remarks/Arguments

The Claims

Claims 10-20, 27-29 and 40-53 are currently pending in the application with Claims 48-51 being withdrawn from further consideration as being drawn to a non-elected species.

Notice of Non-Complaint Amendment

In the communication of July 20, 2009, the Examiner noted that the amendments filed on December 19, 2007 and March 24, 2004 were considered non-compliant because Claims 48-51 drawn to non-elected species and withdrawn from further consideration were not indicated as "withdrawn" in the listing of claims.

Claims 48-51 have been cancelled in the Preliminary Amendment filed herewith, thereby bringing the amendment into compliance.

Preliminary Amendment

Applicants hereby cancel Claims 10-20, 27-29 and 46-51 without prejudice or disclaimer and add new Claims 54-58. Upon cancellation of these claims, Claims 40-45 and 52-58 will be pending in the application.

Claim 40 has been amended to recite an antibody or antigen binding domain which recognizes a DE epitope on human OPGbp "wherein the DE epitope comprises the amino acid sequence from residues 212 to 250 of human OPGbp as shown in Figure 29 (SEQ ID NO: 158)". Support for this amendment is found at p. 38, line 33 to p. 39, line 5 of the specification.

Claim 41 has been amended to recite a DE epitope that "comprises residues 230 to 234 of human OPGbp". Support for this amendment is found at p. 39, lines 12-18 of the specification.

New Claims 54-58 are supported at various locations in the specification, including p. 32, lines 8-12; p. 33, lines 5-12; and p. 72, lines 8-12 of the specification.


The new and amended claims do not add new matter or raise new issues requiring further searching and consideration. Applicants respectfully request entry of the new and amended claims.

CONCLUSION

Claims 40-45 and 52-58 are in condition for allowance and a notice thereof is solicited.

Although Applicants believe that no fee is due herewith, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: August 21, 2009

Please send all future correspondence to:
21069
US Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Electronic Acknowledgement Receipt

EFS ID:	5935579		
Application Number:	09791153		
International Application Number:			
Confirmation Number:	7448		
Title of Invention:	Selective binding agents of osteoprotegerin binding protein		
First Named Inventor/Applicant Name:	Rajendra V. Deshpande		
Correspondence Address:	U.S. Patent Operations/RBW Dept. 4300, M/S 27-4-A AMGEN, INC. One Amgen Center Drive Thousand Oaks	CA	91320-1799
Filer:	Robert B. Winter/Nola Diamond		
Filer Authorized By:	Robert B. Winter		
Attorney Docket Number:	A-633A		
Receipt Date:	21-AUG-2009		
Filing Date:	22-FEB-2001		
Time Stamp:	22:12:26		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment	no
File Listing:	

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	SimonetCell1997.pdf	1137987 05430e09e5d4d90b1a7bf9e33134fb73ea5266a	no	11
Warnings:					
Information:					
2	NPL Documents	SkolnickTrendsInBiotech2000.pdf	6195199 138fc0763421ea9cf894d0944fc0f995a5b14273	no	6
Warnings:					
Information:					
3	NPL Documents	SmithCell1994.pdf	483706 7e38cd5aa6e6997c2edc1e18a4fb4bf7543708	no	5
Warnings:					
Information:					
4	NPL Documents	StamenkovicEMBO_J1989.pdf	816885 5f5b399c034a30099c290db5c5ab5118b477	no	8
Warnings:					
Information:					
5	NPL Documents	StressgenProdUseSheet-RANKL_TRANCEMonoclonalAB-Clone12A668.pdf	73049 4091988904f58b9d123c77a5f4a28e72e04d93	no	1
Warnings:					
Information:					
6	NPL Documents	SudaBone1995.pdf	491833 971d986ccb3d4f11d1ceefc96ce3559ba28246	no	5
Warnings:					
Information:					
7	NPL Documents	SudaEndocRevMonograph1995.pdf	467505 304fb705530a5ca1f672fd118222fb930a90fd	no	5
Warnings:					
Information:					
8	NPL Documents	SudaEndocrineRev1999.pdf	1273553 de48004c12chao4ffef081885f3d1681006453	no	14
Warnings:					
Information:					
9	NPL Documents	TakadaBoneMineral1992.pdf	1782601 92fb93be93c0fe0990de754609346465841e996226	no	15

Warnings:					
Information:					
10	NPL Documents	TakeyamaBioChemBiophysResComm2000.pdf	438718 e0fbf8ec388e0006f9d15440054092fb8 cebc	no	6
Warnings:					
Information:					
11	NPL Documents	TengJClinInvest2000.pdf	1278975 4f9442e9fd88e153d491b2fb167c746 2ef	no	18
Warnings:					
Information:					
12	NPL Documents	TsudaBioChemBiophysResComm1997.pdf	549605 ccf8556dab6c51b6edfa3378fb90b5c10b 22e40b	no	7
Warnings:					
Information:					
13	NPL Documents	UdagawaBone1999.pdf	682032 01005e1b100a781b4e993e2ff154a66b3 9213	no	8
Warnings:					
Information:					
14	NPL Documents	VineyJImmuno1998.pdf	367004 8d9f548000e92e67fbb931c7c2fe4629b 8e42	no	11
Warnings:					
Information:					
15	NPL Documents	WatanabeBioChemBiophysResComm1990.pdf	876623 8ef073ccedfb68a1ca2fb9910a68a154dc0 247b	no	8
Warnings:					
Information:					
16	NPL Documents	WillardProteinExpressionPurification2000.pdf	922887 c134312cf0488bae2500fb005cf981a6 dal	no	11
Warnings:					
Information:					
17	NPL Documents	WongJBiolChem1997.pdf	421575 d87cc4f5ed1d1591597fb91a3897caef 484	no	5
Warnings:					
Information:					
18	NPL Documents	ShalhoubJCellBiochem1999.pdf	3615910 a34ba5cc00a00f4d2eb2b66a9b166ef 3ff	no	11

Warnings:					
Information:					
19	NPL Documents	SudaEndocRev1992.pdf	1161023 dfe621c9cbbe8bc2c87791728fb9d 2b255	no	1
Warnings:					
Information:					
20	NPL Documents	WileyImmunity1995.pdf	8407990 42c6927bfc9f6863312ff9b1029ae02a5c81 910b	no	10
Warnings:					
Information:					
21	NPL Documents	WongJExpMed1997.pdf	5188582 79a9bb3c911681503e761efbb2f244ff4 49eb	no	6
Warnings:					
Information:					
22	NPL Documents	WongJBioChem1998.pdf	402415 3e5ace7abfc09c739c952817e237bf9a07a 029e	no	5
Warnings:					
Information:					
23	NPL Documents	XuImmunity1996.pdf	686913 6c2e5034ff5fd1d31e165361d68680677c 0894	no	9
Warnings:					
Information:					
24	NPL Documents	YangProcNatlAcadSciUSA1985. pdf	4566471 8c22bc0fffbadbed31a7e7cb1a0ec12b98 670c	no	5
Warnings:					
Information:					
25	NPL Documents	YasudaPNAS1998.pdf	336481 8b64b70341a5b2ff135f62f9c27725c5a0 3618	no	6
Warnings:					
Information:					
26	NPL Documents	YonedaCancerRes1995.pdf	550720 ffbd1ac15eb0a6ed39a4cd20d2d5a19 0818	no	6
Warnings:					
Information:					
27	NPL Documents	YunImmunol1998.pdf	1303007 da0f1235b7f5cf88940dec1dab9e0 062a	no	9

Warnings:					
Information:					
28	NPL Documents	ZhangJBiolChem2001.pdf	568959 622ze3kc4B0748feea2d8fb7d603470f2 Tabd	no	6
Warnings:					
Information:					
29	NPL Documents	HymowitzBiochemistry2000.pdf	545746 9386392e2faa71a05ee4253472b4d102c1 7726	no	8
Warnings:					
Information:					
30	NPL Documents	MongkolsapayaNatureStructBiology1999.pdf	6938798 2991525acfe1ef61aae4ed16e78a9646e1eb 604d	no	6
Warnings:					
Information:					
31	NPL Documents	ParslowMedImmuno1997.pdf	1810718 d11ae44908fc0559b094fb15e7e005c00ec0 499b4	no	11
Warnings:					
Information:					
32	NPL Documents	Chalmcommunity1999.pdf	8632804 1c1c21b15493eb208bc5da3c76earfb65cf 5e05f	no	9
Warnings:					
Information:					
33	Information Disclosure Statement (IDS) Filed (SB/08)	A-633ASupp1449-5of5-082109.pdf	600762 6af64a1c02de140d0ea3ce91be0d4c45775 d4692	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
34	Power of Attorney	A-633APowerOfAtty082109.pdf	51685 0d72ed44dd4dd7c1411131762d3969c9 71061	no	1
Warnings:					
Information:					
35		A-633A-ResponseToNotice082109.pdf	155654 18c6c8111fbca375421a944b64d4c0fbc 0730	yes	5
Multipart Description/PDF files in .zip description					
Document Description			Start	End	

	Preliminary Amendment	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	5

Warnings:

Information:

Total Files Size (in bytes):

63784375

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.